BIXTOTCPharmaceutical PreparationsFiscal year ends December 31

BIOXYTRAN, INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.02−0.00 (-3.95%)

Close on Oct 19, 2026

Market cap: $2.56M
P/E (TTM): –
Dividend yield: –

BIOXYTRAN, INC income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	–	–	–	–	–	–	–	–	0.19	0.25	0.26	0.28	0.42	0.31	0.08	0.02	–
Cost of Revenue	–	–	–	–	–	–	–	–	0.10	0.10	0.14	0.17	0.20	0.12	0.02	0.00	–
Gross Profit	–	–	–	–	–	–	–	–	0.09	0.15	0.12	0.11	0.22	0.19	0.06	0.01	–
Research & Development	0.45	0.11	1.15	1.28	2.01	0.54	–	–	–	–	–	–	–	–	–	–	–
Selling, General & Admin	–	–	–	–	–	–	–	–	0.40	0.82	2.21	1.39	2.19	2.48	4.49	0.34	–
General & Administrative	0.65	1.17	1.40	0.83	1.61	0.48	0.51	0.22	–	–	–	–	–	–	–	–	–
Operating Expenses	1.84	2.22	3.80	2.44	4.21	1.27	1.63	0.22	0.40	0.82	2.21	1.39	2.19	2.48	4.49	–	–
Operating Income	-1.84	-2.22	-3.80	-2.44	-4.21	-1.27	-1.63	-0.22	-0.31	-0.67	-2.09	-1.28	-1.97	-2.29	-4.43	-0.33	–
Interest Expense	0.13	0.08	0.19	–	2.02	1.01	0.04	0.00	0.01	0.01	0.01	0.01	0.01	0.00	0.01	0.01	–
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.00	0.00	–
Other Non-Operating Income	-0.28	-0.16	-0.76	-0.23	-0.31	-1.27	-0.23	-0.08	-0.01	-0.03	-0.01	-0.07	0.19	0.00	0.00	-0.01	–
Asset Impairment Charges	0	0	0	0	0	–	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	-2.12	-2.38	-4.56	-2.67	-4.53	-2.54	-1.86	-0.30	–	-0.70	-2.10	-1.35	-1.78	–	–	–	–
Income Tax Expense	–	–	–	–	–	–	–	0.00	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-2.12	-2.38	-4.56	-2.67	-4.53	-2.48	-1.86	-0.30	–	–	–	–	–	–	-4.43	-0.34	-0.28
Minority Interest in Earnings	–	-0.01	-0.09	-0.19	-0.50	-0.06	–	–	–	–	–	–	–	–	–	–	–
Net Income	-2.12	-2.37	-4.47	-2.47	-4.03	-2.54	-1.86	-0.30	-0.32	-0.70	-2.10	-1.35	-1.78	-2.29	-4.43	–	–
Net Income to Common	–	–	–	–	-4.03	-2.48	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-0.02	-0.02	-0.03	-0.02	-0.04	-0.03	-0.02	0.00	-0.01	-0.03	-0.21	-0.30	-0.47	-1.00	-3.00	-0.50	–
EPS (Diluted)(per share)	-0.02	-0.02	-0.03	-0.02	-0.04	-0.03	-0.02	0.00	-0.01	-0.03	-0.21	-0.30	-0.47	-1.00	-3.00	-0.50	–
Shares Outstanding (Basic, Weighted)(shares)	92	139	134	113	106	94	86	85	39	27	10	4.45	3.75	2.64	1.41	–	–
Shares Outstanding (Diluted, Weighted)(shares)	92	139	134	113	106	94	86	85	39	27	10	4.45	3.75	2.64	1.41	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 96.9%

Financial strength

Current ratio: 0.03
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 3.4%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –